Passage Bio rises as nerve disorder therapy shows promise in study
14/12/2022 13:14
** Shares of gene therapy co Passage Bio PASG.O rise 10.5%
to $1.26 premarket
** Co announces positive interim data from early-stage study
testing of an experimental therapy to treat pediatric patients
with GM1 Gangliosidosis, an inherited disorder that
progressively destroys nerve cells in brain and spinal cord
** Low and high dose of drug found to be well tolerated with
a favorable safety profile
** Drug showed dose-dependent improvements in clinical
activity when delivered through injection to a region called
cisterna magna at the base of the brain - PASG
** Co has completed dosing of all patients and expects to
report initial data from 4th cohort by mid-2023
** Stock down 82% YTD, as of last close
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))